Sarepta sinks after lowering 2025 product revenue forecast

Shares of gene therapy maker Sarepta Therapeutics SRPT.O fall 21.3% to $36.80 in aftermarket trade

Company sees 2025 net product revenue of $2.3 billion to $2.6 billion, compared to previous expectation of $2.9 billion to $3.1 billion

Company reports adjusted Q1 loss of $3.42/shr, vs analysts' average loss estimate of 95 cents/shr, according to data compiled by LSEG

SRPT shares, along with those of other gene therapy developers, had plummeted earlier in the day after the U.S. FDA named Vinay Prasad as the director of its Center for Biologics Evaluation and Research

Up to last close, stock down 61.7% YTD